Search results
22 gru 2021 · A 3-day course of remdesivir had an acceptable safety profile and prevented disease progression resulting in hospitalization among high-risk patients with Covid-19.
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
The early use of remdesivir in outpatients with Covid-19 who...
- Free Full Text
A total of 1062 patients underwent randomization (with 541...
- Editorial Jan 27, 2022 The Goldilocks Time for Remdesivir — Is Any Indication Just Right E.L. Heil and S. Kottilil
Gottlieb et al. conducted a clinical trial — the results of...
- Original Article Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma H. Tilly and Others
Diffuse large B-cell lymphoma (DLBCL) is typically treated...
- Original Article Cardiovascular and Cancer Risk With Tofacitinib in Rheumatoid Arthritis S.R. Ytterberg and Others
We report results from the Oral Rheumatoid Arthritis Trial...
- Interactive Medical Case Up in The Air J.V. Loewenthal and Others
Download; 307.76 KB; Information & Authors Information...
- Editorial The Price of Freedom From Tricuspid Regurgitation J. Chikwe and M. Gaudino
From the Department of Cardiac Surgery, Smidt Heart...
- Perspective Please Don't Keep Me A. Drutchas
After her grandmother attempts suicide, a physician finds...
- Correspondence Mar 17, 2022 Outpatient Remdesivir to Prevent Progression to Severe Covid-19
Chcieliśmy się dowiedzieć, czy remdesiwir jest skuteczny w leczeniu chorych na COVID-19 i czy jego stosowanie wiąże się z występowaniem niepożądanych skutków, w porównaniu z placebo lub standardową opieką.
14 wrz 2021 · Here we report the results of the DisCoVeRy trial comparing remdesivir to control in hospitalised patients with COVID-19. Remdesivir administration was well tolerated but was neither associated with a better clinical outcome at day 15 and 29 nor with a faster viral clearance.
16 lut 2022 · The early use of remdesivir in outpatients with Covid-19 who are at high risk for disease progression reduces the risk of hospitalization and death, as reported in our double-blind,...
21 lut 2023 · Since the outbreak of the COVID-19 pandemic, immense efforts have been made to find effective treatments for the disease. 1–3 The broad-spectrum antiviral medication remdesivir was identified as a promising therapeutic candidate because of its ability to inhibit coronaviruses in vitro—including SARS-CoV-2, which causes COVID-19. 4–6 For ...
27 maj 2020 · In this report, we describe the results of an open-label, randomized, multicenter trial evaluating the efficacy and safety of treatment with remdesivir for 5 or 10 days in patients with severe...
30 lip 2020 · Both trials evaluated remdesivir given intravenously at a dose of 100 mg per day for 10 days. Gilead Sciences, the manufacturer of remdesivir, provided the drug free for both trials and was involved in protocol development in the ACTT trial.
